Alphabet, Inc., the parent company of Google, plans to develop a life-long gene therapy for heart disease, the leading cause of death for men and women in the U.S.
Attaining this lofty goal will be the job of Alphabet’s gene-editing start-up, Verve Therapeutics, and Google’s life science start-up, Verily.
This month, Google’s venture fund, GV, partnered with three other funds to launch Verve Therapeutics with $58.5 million in Series A funding. The company’s scientific founders include Dr. Sekar Kathiresan (CEO), Dr. Kiran Musunuru (chief scientific adviser) and Dr. J. Keith Joung (strategic adviser).
Read more
Comments are closed.